ESMO 2022 Conference Coverage


 

ESMO 2022 Evaluation of the DNA Damage Response Network as a Predictor of Nivolumab Efficacy in HNSCC

86 views
September 19, 2022
0 Comments
Login to view comments. Click here to Login
Head and Neck